Section 70
Chapter 69,884

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan) , gastrointestinal (GI) , or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Yao, J.C.; Strosberg, J.; Fazio, N.; Pavel, M.E.; Ruszniewski, P.; Bergsland, E.; Li, D.; Tafuto, S.; Raj, N.; Campana, D.; Hijioka, S.; Raderer, M.; Guimbaud, R.; Gajate, P.; Pusceddu, S.; Reising, A.; Degtyarev, E.; Mookerjee, B.; Aimone, P.; Singh, S.

Annals of Oncology Official Journal of the European Society for Medical Oncology 29 Suppl. 8: Viii 467-Viii 468


ISSN/ISBN: 0923-7534
PMID: 32137198
DOI: 10.1093/annonc/mdy293.001
Accession: 069883923

Download citation:  

PDF emailed within 0-6 h: $19.90